Absence of STAT1 in donor-Derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD

Blood

Volumn 124, Issue 12, 2014, Pages 1976-1986

  Capitini, Christian M ^a   Nasholm, Nicole M ^b   Chien, Christopher D ^b   Larabee, Shannon M ^b   Qin, Haiying ^b   Song, Young K ^b   Klover, Peter J ^c   Hennighausen, Lothar ^c   Khan, Javed ^b   Fry, Terry J ^b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CALGRANULIN A; CALGRANULIN B; CD45 ANTIGEN; FREE RADICAL; INTERLEUKIN 10; INTERLEUKIN 12; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; STAT1 PROTEIN; STAT3 PROTEIN; S100A8 PROTEIN, MOUSE; S100A9 PROTEIN, MOUSE; STAT1 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL EXPANSION; CELL ISOLATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PLASMACYTOID DENDRITIC CELL; PROTEIN DEPLETION; REGULATORY T LYMPHOCYTE; 129 MOUSE; ADVERSE EFFECTS; ALLOGRAFT; ANIMAL; BONE MARROW TRANSPLANTATION; C3H MOUSE; C57BL MOUSE; DEFICIENCY; DENDRITIC CELL; DONOR; FEMALE; GENETICS; GRAFT VS HOST DISEASE; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; T LYMPHOCYTE; TRANSGENIC MOUSE; TRANSPLANTATION;

ALLOGRAFTS; ANIMALS; BONE MARROW TRANSPLANTATION; CALGRANULIN A; CALGRANULIN B; DENDRITIC CELLS; FEMALE; GENE EXPRESSION; GRAFT VS HOST DISEASE; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TISSUE DONORS;

EID: 84907225024     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-500876     Document Type: Article

References (52)

1. Kolb H-J. Graft-Versus-Leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371-4383
2. Blazar BR, Murphy WJ, Abedi M. Advances in graft-Versus-Host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443-458
3. Paczesny S, Choi SW, Ferrara JLM. Acute graftversus- host disease: New treatment strategies. Curr Opin Hematol. 2009;16(6):427-436
4. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-Presenting cells. Science. 1999;285(5426):412-415
5. Robb RJ, Hill GR. The interferon-Dependent orchestration of innate and adaptive immunity after transplantation. Blood. 2012;119(23): 5351-5358
6. Capitini CM, Herby S, Milliron M, Anver MR, Mackall CL, Fry TJ. Bone marrow deficient in IFN-Gamma signaling selectively reverses GVHD-Associated immunosuppression and enhances a tumor-Specific GVT effect. Blood. 2009;113(20):5002-5009
7. Robb RJ, Kreijveld E, Kuns RD, et al. Type I-IFNs control GVHD and GVL responses after transplantation. Blood. 2011;118(12):3399-3409
8. Choi J, Ziga ED, Ritchey J, et al. IFNgR signaling mediates alloreactive T-Cell trafficking and GVHD. Blood. 2012;120(19):4093-4103
9. Li H, Matte-Martone C, Tan HS, et al. Graft-Versus-Host disease is independent of innate signaling pathways triggered by pathogens in host hematopoietic cells. J Immunol. 2011; 186(1):230-241
10. Delisle J-S, Gaboury L, Bélanger M-P, Tassé E, Yagita H, Perreault C. Graft-Versus-Host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-Gamma receptordeficient hosts. Blood. 2008;112(5):2111-2119
11. Sun K, Hsiao H-H, Li M, et al. IFN-G receptordeficient donor T cells mediate protection from graft-Versus-Host disease and preserve graft-Versus-tumor responses after allogeneic bone marrow transplantation. J Immunol. 2012; 189(4):2033-2042
12. Ma H, Lu C, Ziegler J, et al. Absence of Stat1 in donor CD4∗ T cells promotes the expansion of Tregs and reduces graft-Versus-Host disease in mice. J Clin Invest. 2011;121(7):2554-2569
13. Platanias LC. Mechanisms of type-I- and type-II-Interferon-Mediated signalling. Nat Rev Immunol. 2005;5(5):375-386
14. Ma H-H, Ziegler J, Li C, et al. Sequential activation of inflammatory signaling pathways during graft-Versus-Host disease (GVHD): Early role for STAT1 and STAT3. Cell Immunol. 2011; 268(1):37-46
15. Sugerman PB, Faber SB, Willis LM, et al. Kinetics of gene expression in murine cutaneous graftversus- host disease. Am J Pathol. 2004;164(6): 2189-2202
16. Wilhelm K, Ganesan J, Müller T, et al. Graftversus- host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010;16(12): 1434-1438
17. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-Bet1 cytotoxic effectors and type I interferon-Mediated processes in chronic graft-Versus-Host disease of the oral mucosa. Blood. 2009;113(15):3620-3630
18. Kimura T, Kadokawa Y, Harada H, et al. Essential and non-Redundant roles of p48 (ISGF3 g) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells. 1996;1(1):115-124
19. Klover PJ, Muller WJ, Robinson GW, Pfeiffer RM, Yamaji D, Hennighausen L. Loss of STAT1 from mouse mammary epithelium results in an increased Neu-Induced tumor burden. Neoplasia. 2010;12(11):899-905
20. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239
21. Wang H, Li Y, Liu H, et al. Peroxynitrite mediates glomerular lesion of diabetic rat via JAK/STAT signaling pathway. J Endocrinol Invest. 2009; 32(10):844-851
22. Couto FM, Minn AH, Pise-Masison CA, et al. Exenatide blocks JAK1-STAT1 in pancreatic beta cells. Metabolism. 2007;56(7):915-918
23. Pugazhenthi U, Velmurugan K, Tran A, Mahaffey G, Pugazhenthi S. Anti-Inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients. Diabetologia. 2010;53(11):2357-2368
24. Schroder K, Spille M, Pilz A, et al. Differential effects of CpG DNA on IFN-Beta induction and STAT1 activation in murine macrophages versus dendritic cells: Alternatively activated STAT1 negatively regulates TLR signaling in macrophages. J Immunol. 2007;179(6): 3495-3503
25. Björck P, Leong HX, Engleman EG. Plasmacytoid dendritic cell dichotomy: Identification of IFN-A producing cells as a phenotypically and functionally distinct subset. J Immunol. 2011; 186(3):1477-1485
26. Fallarino F, Bianchi R, Orabona C, et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med. 2004; 200(8):1051-1062
27. Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ. INTERFEROME: The database of interferon regulated genes. Nucleic Acids Res. 2009; 37(Database issue suppl 1):D852-D857
28. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-Derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008; 205(10):2235-2249
29. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809
30. Stojanovic T, Wagner AH, Wang S, et al. STAT-1 decoy oligodeoxynucleotide inhibition of acute rejection in mouse heart transplants. Basic Res Cardiol. 2009;104(6):719-729
31. Stojanovic T, Scheele L, Wagner AH, et al. STAT-1 decoy oligonucleotide improves microcirculation and reduces acute rejection in allogeneic rat small bowel transplants. Gene Ther. 2007;14(11):883-890
32. Leng C, Gries M, Ziegler J, et al. Reduction of graft-Versus-Host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol. 2006;34(6):776-787
33. Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-Versushost disease. Blood. 2014;123(24):3832-3842
34. Wang H, Yang Y, Sharma N, et al. STAT1 activation regulates proliferation and differentiation of renal progenitors. Cell Signal. 2010;22(11):1717-1726
35. Ochando JC, Homma C, Yang Y, et al. Alloantigen-Presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol. 2006;7(6):652-662
36. Goubier A, Dubois B, Gheit H, et al. Plasmacytoid dendritic cells mediate oral tolerance. Immunity. 2008;29(3):464-475
37. Koyama M, Hashimoto D, Aoyama K, et al. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-Versus-Host disease as antigen-Presenting cells. Blood. 2009;113(9): 2088-2095
38. Banovic T, Markey KA, Kuns RD, et al. Graftversus- host disease prevents the maturation of plasmacytoid dendritic cells. J Immunol. 2009; 182(2):912-920
39. Lu Y, Giver CR, Sharma A, et al. IFN-G and indoleamine 2,3-Dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood. 2012;119(4):1075-1085
40. Li J-M, Southerland LT, Lu Y, et al. Activation, immune polarization, and graft-Versus-Leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-Presenting cells in allogeneic hemopoietic stem cell transplantation. J Immunol. 2009;183(12): 7799-7809
41. Hadeiba H, Sato T, Habtezion A, Oderup C, Pan J, Butcher EC. CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-Versus-Host disease. Nat Immunol. 2008;9(11):1253-1260
42. Li H, Demetris AJ, McNiff J, et al. Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-Versus-Host disease induction. J Immunol. 2012;188(8):3804-3811
43. Rajasekar R, Mathews V, Lakshmi KM, et al. Plasmacytoid dendritic cell count on day 28 in HLA-Matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD. Biol Blood Marrow Transplant. 2008;14(3):344-350
44. Watanabe N, Narita M, Furukawa T, et al. Kinetics of pDCs, mDCs, γdT cells and regulatory T cells in association with graft versus host disease after hematopoietic stem cell transplantation. Int J Lab Hematol. 2011;33(4):378-390
45. Fagnoni FF, Oliviero B, Giorgiani G, et al. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood. 2004;104(1): 281-289
46. Mohty M, Blaise D, Faucher C, et al. Impact of plasmacytoid dendritic cells on outcome after reduced-Intensity conditioning allogeneic stem cell transplantation. Leukemia. 2005; 19(1):1-6
47. Jackson SH, Yu C-R, Mahdi RM, Ebong S, Egwuagu CE. Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J Immunol. 2004;172(4):2307-2315
48. Asselin-Paturel C, Brizard G, Pin JJ, Brière F, Trinchieri G. Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol. 2003;171(12):6466-6477
49. Kim HS, Lee M-S. Essential role of STAT1 in caspase-Independent cell death of activated macrophages through the p38 mitogen-Activated protein kinase/STAT1/reactive oxygen species pathway. Mol Cell Biol. 2005;25(15):6821-6833
50. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-Dependent inflammatory gene activation. J Biol Chem. 2006;281(20):14111-14118
51. Stephanou A, Latchman DS. Opposing actions of STAT-1 and STAT-3. Growth Factors. 2005; 23(3):177-182
52. Moseman EA, Liang X, Dawson AJ, et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol. 2004;173(7):4433-4442